Related Experiment Videos
[Clinical experience with S-1108 on bacterial infection in the pediatric field]
Insights
S-1108, a new oral antibiotic, demonstrated 100% clinical efficacy in treating pediatric bacterial infections. This novel cephem antibiotic showed no adverse effects, suggesting its potential as a safe and effective treatment option for children.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Microbiology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- Development of novel, safe, and effective antibiotics is crucial for combating pediatric infections.
- Cephem antibiotics represent a class of valuable antimicrobial agents.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of S-1108, an orally active cephem antibiotic.
- To assess the bacteriological eradication rates of S-1108 in pediatric patients.
- To determine the potential utility of S-1108 in treating various pediatric bacterial infections.
Main Methods:
- Oral administration of S-1108 at a daily dose of 9.3-12.4 mg/kg in three divided doses for 5-11 days.
- Study included pediatric patients diagnosed with pharyngitis, tonsillitis, bronchitis, pneumonia, lymphadenitis, enteritis, and cystitis.
- Clinical and bacteriological outcomes were assessed, along with monitoring for side effects and laboratory abnormalities.
Main Results:
- Achieved a 100% clinical efficacy rate, with 3 excellent and 6 good responses.
- Successfully eradicated key bacterial pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, Klebsiella pneumoniae, and Haemophilus influenzae.
- No clinical side effects or laboratory test abnormalities were reported during the study period.
Conclusions:
- S-1108 demonstrated high clinical effectiveness and an excellent safety profile in pediatric patients.
- The antibiotic achieved significant bacteriological eradication, supporting its antimicrobial activity.
- S-1108 shows promise as a valuable therapeutic option for managing bacterial infections in the pediatric field.
Abstract:
The effects of S-1108, an orally active cephem antibiotic newly synthesized by Shionogi Res. Lab., on pediatric bacterial infections was studied. S-1108 was administered orally at a daily dose between 9.3 and 12.4 mg/kg in three divided doses (after each meal) for 5 to 11 days to patients with pharyngitis (2), tonsillitis (1), bronchitis (3), pneumonia (1), lymphadenitis (1), enteritis (1) and cystitis (1). The clinical efficacy rate was 100% with excellent responses in 3, good in 6 and undetermined in 1. Bacteriological effects observed indicated that one strain each of Streptococcus pneumoniae, Streptococcus pyogenes, Klebsiella pneumoniae and two strains of Haemophilus influenzae were eradicated by the treatment. No clinical side effects and laboratory test abnormalities were observed at all in this study. These results suggested that S-1108 would be a useful antibiotic for the treatment of bacterial infections in the pediatric field.